拨康视云正式上市 百惠担任联席账簿管理人及联席牵头经办人

Group 1 - Cloudbreak Pharma Inc. (stock code 2592.HK) officially listed on the Hong Kong Stock Exchange on July 3, 2025, with an IPO price of HKD 10.10 per share, achieving nearly 78 times oversubscription [1] - The IPO project received cornerstone investment of approximately USD 2.8 million from The Reynold Lemkins Group (Asia) Limited, facilitated by the professional recommendations of the Baihui Financial team [1] - The global offering consisted of approximately 60.582 million shares, with a subscription period from June 24 to June 27, 2025, and an expected net fundraising amount of up to HKD 610 million [1] Group 2 - The company plans to allocate the proceeds from the IPO as follows: approximately 62.4% for ongoing clinical research and development of core product CBT-001, about 27.6% for costs related to ongoing clinical research and registration of CBT-009, around 5.5% for production facilities and commercialization activities, and the remaining 4.5% for working capital and other general corporate purposes [3] - CBT-001 is the world's first innovative drug for pterygium entering Phase III clinical trials, targeting VEGFR and PDGFR to precisely regulate abnormal vascular growth on the ocular surface [8] - As of May 2025, CBT-001 has completed patient enrollment in multi-center Phase III clinical trials in China, the United States, and Australia, with plans to submit dual market applications in China and the U.S. in 2025 [8] Group 3 - Baihui Financial anticipates that with CBT-004 completing Phase II clinical trials in the U.S., CBT-001 is expected to be launched in 2026, marking the company's transition from a research-driven entity to a commercialization phase [10] - The company plans to establish sales branches in major global markets within the next three years while accelerating the clinical advancement of CBT-009, aiming to build a differentiated competitive advantage in the field of ophthalmic innovative drugs through technological innovation and global expansion [10]